Io Biotech, Inc. (IOBT)
$1.46
Insights on Io Biotech, Inc.
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 49.7% return, outperforming this stock by 71.2%
Performance
- $1.43$1.50$1.46
1.92%
Downside
Day's Volatility :4.53%
Upside
2.67%
- $0.82$2.64$1.46
44.09%
Downside
52 Weeks Volatility :69.08%
Upside
44.7%
Returns
| Period | Io Biotech, Inc. | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -20.22% | 1.7% | 0.0% |
6 Months | 52.08% | 11.3% | 0.0% |
1 Year | -21.51% | 5.4% | 1.3% |
3 Years | -90.67% | 13.9% | -22.1% |
Highlights
Market Capitalization | 96.8M |
Book Value | $2.02 |
Earnings Per Share (EPS) | -1.98 |
Wall Street Target Price | 8.0 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -37.78% |
Return On Equity TTM | -63.29% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -91.2M |
Diluted Eps TTM | -1.98 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.35 |
EPS Estimate Next Year | -1.3 |
EPS Estimate Current Quarter | -0.39 |
EPS Estimate Next Quarter | -0.36 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 447.95%
Technicals Summary
Sell
Neutral
Buy
Io Biotech, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Io Biotech, Inc. | -15.61% | 52.08% | -21.51% | -90.67% | -90.67% |
 Moderna, Inc. | -1.39% | 41.81% | -19.31% | -38.71% | 322.88% |
 Regeneron Pharmaceuticals, Inc. | -5.68% | 13.74% | 14.81% | 80.88% | 159.02% |
 Novo Nordisk A/s | -2.24% | 29.49% | 49.67% | 240.51% | 421.0% |
 Vertex Pharmaceuticals Incorporated | -3.67% | 10.39% | 20.74% | 84.71% | 129.52% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Io Biotech, Inc. | NA | NA | NA | -1.35 | -0.63 | -0.38 | NA | 2.02 |
Moderna, Inc. | 24.73 | NA | 0.0 | -6.77 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 26.13 | 26.13 | 1.46 | 45.02 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 48.36 | 48.36 | 2.4 | 3.34 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 29.17 | 29.17 | 0.53 | 16.75 | 0.23 | 0.13 | NA | 68.22 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Io Biotech, Inc. | Buy | $96.8M | -90.67% | NA | 0.0% |
Moderna, Inc. | Buy | $41.3B | 322.88% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $99.6B | 159.02% | 26.13 | 30.14% |
Novo Nordisk A/s | Buy | $573.9B | 421.0% | 48.36 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $104.7B | 129.52% | 29.17 | 36.68% |
Institutional Holdings
Vivo Capital, LLC
9.37%Novo A/S
8.72%Samsara BioCapital, LLC
5.53%Morgan Stanley - Brokerage Accounts
3.46%Marshall Wace Asset Management Ltd
3.20%Armistice Capital, LLC
2.92%
Corporate Announcements
Io Biotech, Inc. Earnings
Io Biotech, Inc.’s price-to-earnings ratio stands at None
Read More
Company Information
io biotech is a clinical stage biotech company developing disruptive immune therapies for immunological treatment of cancer. our pipeline of first-in-class immune modulating anti-cancer therapies is based on a unique platform technology enabling the activation of t cells that are specific for immune inhibitory molecules. io biotech has achieved a proven track record of progressing compounds to the clinic, and has two lead immune modulating anti-cancer therapies targeting ido and pd-l1 in clinical development and several compounds finalizing preclinical phase. io biotech has an experienced management team within immuno-oncology fields and a world-class advisory board.
Organization | Io Biotech, Inc. |
Employees | 68 |
CEO | Dr. Mai-Britt Zocca Ph.D. |
Industry | Services |
